PathAI

PathAI is an artificial intelligence and digital pathology company that develops technology to improve the analysis of tissue samples and support better medical and research outcomes. Founded in 2016, the company combines machine learning, computational pathology, medical expertise, and digital laboratory technology to help pathologists and life-sciences organizations examine tissue images more efficiently. Its solutions are designed for pathology laboratories, academic medical centers, healthcare systems, pharmaceutical companies, biotechnology organizations, and clinical research teams.

The company’s main objective is to improve the accuracy, consistency, and efficiency of pathology analysis. Traditional pathology often involves examining tissue samples through glass slides using microscopes. Digital pathology converts these slides into high-resolution digital images that can be viewed, managed, analyzed, and shared through specialized software. PathAI applies AI models to these digital images to identify tissue structures, quantify biomarkers, assess cellular characteristics, and generate information that can support diagnostic and research workflows.

One of PathAI’s central products is AISight, a cloud-native digital pathology image management system. AISight provides a central environment for managing pathology cases, digital slides, image data, and AI applications. It is designed to help laboratories organize their digital pathology operations while providing pathologists with tools for viewing and reviewing tissue images. The platform supports case management, image ingestion, slide viewing, collaboration, and access to AI-powered analysis. Its open architecture also allows laboratories to work with selected third-party AI applications rather than relying exclusively on one software provider.

AISight is built to support different laboratory workflows and can be configured for the needs of individual institutions. Pathologists can use the platform to review digital slides, manage cases, and access supported image-analysis algorithms. Its browser-based and cloud-based design helps organizations manage digital pathology data without depending entirely on local infrastructure. The platform also provides image and data storage capabilities intended to support laboratory operations and research activities.

An important feature of AISight is its interoperability. PathAI describes the platform as scanner-agnostic, with compatibility across major digital pathology scanner systems. Its published compatibility information identifies systems from Hamamatsu, Leica, Roche, and Philips. AISight can also work with most major laboratory information systems, helping laboratories connect digital slide management with their existing operational processes. This flexibility is important for organizations that already use established scanning equipment and laboratory software and want to introduce AI capabilities without replacing every part of their infrastructure.

PathAI also provides AISight Dx, a digital pathology platform designed for clinical diagnostic workflows. Unlike research-only applications, AISight Dx has received regulatory clearance for primary diagnosis in the United States and carries CE-IVD marking for primary diagnosis in the European Economic Area, Switzerland, and the United Kingdom. These regulatory distinctions are important because not every PathAI product is approved for clinical diagnostic use. Laboratories should confirm the intended use, regulatory status, and applicable regional requirements of each product before deploying it in patient-care settings.

The company’s AI product portfolio includes tools for biomarker quantification, tissue analysis, research, and clinical development. Its Biomarker Quantification Suite includes products such as AIM-PD-L1 and the AIM-IHC Breast Panel. These tools are designed to analyze immunohistochemistry images and provide automated biomarker measurements. Biomarker quantification is important in cancer research and precision medicine because the presence and distribution of particular proteins or cellular markers can help researchers understand disease characteristics and investigate how patients may respond to treatments.

PathAI also develops tools for analyzing the tumor microenvironment. The tumor microenvironment includes cancer cells, immune cells, connective tissue, blood vessels, and other components surrounding a tumor. Understanding how these elements interact can help researchers investigate disease progression and treatment response. PathAI’s AI-powered image analysis can quantify cellular features and spatial relationships within tissue samples, providing structured information for translational research and drug development.

PathExplore is another important part of the company’s product portfolio. It provides AI-powered pathology analysis designed to extract structured information from whole-slide images. The PathExplore product family supports research into tissue characteristics, disease biology, and biomarker expression. Its applications include oncology and other areas of translational research. PathExplore Fibrosis, for example, is designed to quantify fibrosis, collagen, and related tissue features directly from whole-slide images. These measurements can help researchers investigate disease progression and evaluate potential treatment effects.

PathAI also offers products and research tools for specific disease areas. Its solutions cover oncology, immunology and inflammation, liver disease, inflammatory bowel disease, and other areas of medical research. These products can support the examination of tissue characteristics, biomarker expression, and treatment-related changes. PathAssist is another product family focused on AI-assisted pathology research. PathAssist Derm, for example, supports dermatopathology research workflows and is designed to help analyze digital whole-slide images of skin lesions. Its development is intended to streamline research and support skin cancer investigations. Research-use-only products should not be confused with approved diagnostic applications.

Beyond software products, PathAI provides services for biopharmaceutical companies. Its BioPharma offering combines digital pathology, laboratory services, AI algorithms, and clinical research expertise to support different stages of drug and diagnostic development. These services can help pharmaceutical and biotechnology organizations assess tissue samples, investigate biomarkers, study disease mechanisms, and evaluate treatment responses during clinical development.

The company’s translational research services are designed to turn routine pathology samples into structured data that can be used in scientific investigations. Researchers can use these insights to study disease biology, identify potential biomarkers, and explore relationships between tissue characteristics and clinical outcomes. PathAI’s experience in computational pathology is particularly relevant to oncology, where tissue-based biomarkers can contribute to research into targeted therapies and precision medicine.

PathAI also supports clinical trial pathology workflows. Its clinical development services can include pathology study planning, laboratory operations, sample processing, central pathology review, digital image management, AI-supported analysis, and reporting. These services are intended to help biopharmaceutical organizations manage pathology-related requirements during clinical studies. PathAI’s offering includes support for areas such as metabolic dysfunction-associated steatohepatitis, inflammatory bowel disease, and oncology. The company also provides trial-related data management and pathology expertise to support consistent analysis across research sites.

Another area of its business is real-world pathology data. PathAI develops data products that connect tissue-image information with structured clinical and molecular data. This can help researchers examine relationships between tissue characteristics, patient outcomes, and disease patterns. Carefully curated datasets are important for developing and validating AI models because algorithms need representative examples and reliable annotations to perform consistently across different samples and laboratory environments.

The quality of training data is central to PathAI’s approach. The company reports that its proprietary and contributor-based pathology network includes more than 500 board-certified pathologists and has generated over 42.5 million annotations. These annotations help provide expert guidance for training and evaluating machine-learning models. PathAI also reports a large collection of whole-slide images used in its computational pathology development. The involvement of practicing pathology experts is important because tissue interpretation requires specialized medical knowledge, and AI models must be assessed against meaningful pathology criteria.

PathAI has also developed PLUTO, a pathology foundation model intended to support the development and adaptation of AI applications across different pathology tasks. Foundation models can provide a general representation of tissue-image information that can be adapted for more specific applications. This approach may help developers and researchers build specialized models without starting every project from the beginning. PathAI’s wider AI development work includes different machine-learning approaches and model architectures suited to particular analytical goals.

The company has established partnerships with organizations across the healthcare, diagnostics, and biopharmaceutical industries. Its collaborations have included Roche, Quest Diagnostics, Northwestern Medicine, and other research and laboratory organizations. PathAI has also announced integrations with third-party AI pathology companies, including Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight image management system. These relationships support an ecosystem in which laboratories can access different algorithms and technologies through a shared digital pathology environment.

PathAI’s relationship with Roche has become particularly significant. The companies established a partnership in 2021 and expanded their collaboration in 2024 to develop AI-enabled companion diagnostic algorithms. In May 2026, Roche announced a definitive agreement to acquire PathAI for an upfront payment of $750 million, with additional milestone payments of up to $300 million. Roche’s November 2026 materials describe a combined digital pathology ecosystem built around Roche’s diagnostics capabilities and PathAI’s AISight platform. This relationship is expected to expand the reach of PathAI’s technology and strengthen its role in digital pathology and precision medicine.

PathAI’s products are intended for professional laboratory, clinical, and research environments rather than general consumer use. Organizations adopting its technology may need compatible whole-slide imaging equipment, secure data infrastructure, suitable laboratory information systems, and trained personnel. Implementation can also involve workflow configuration, integration testing, user training, and validation. These requirements mean that PathAI is most relevant to institutions with established pathology operations or organizations planning a broader transition to digital pathology.

Regulatory status and intended use are important considerations when evaluating the platform. AISight research-use-only applications are not intended to be used as standalone diagnostic tools for patient care. AISight Dx has separate regulatory clearances for specified clinical diagnostic uses. Users should verify the applicable product documentation and regional regulatory requirements rather than assuming that every AI algorithm available through the platform has the same authorization.

Overall, PathAI provides a broad collection of digital pathology software, AI algorithms, laboratory services, and research capabilities. AISight serves as the central image and workflow management platform, while products such as AIM-PD-L1, AIM-IHC Breast Panel, PathExplore, and PathAssist address more specialized pathology applications. Its combination of computational pathology expertise, pathologist-supported datasets, laboratory services, and industry partnerships makes it particularly relevant to organizations working in cancer research, biomarker discovery, clinical development, and digital diagnostic workflows.

Pricing

PathAI does not publish standard subscription prices for its enterprise digital pathology platform, AI algorithms, or biopharmaceutical services. Its solutions are offered through business-to-business arrangements, and interested organizations are expected to contact the company or its current Roche Diagnostics channel for product information and commercial terms.

• AISight – Contact for pricing: Enterprise digital pathology image management platform. Pricing depends on laboratory requirements, deployment, and selected capabilities.
• AISight Dx – Contact for pricing: Digital pathology platform for approved clinical diagnostic workflows.
• AI algorithms – Contact for pricing: Specialized tools for biomarker quantification, tissue analysis, and pathology research.
• PathExplore – Contact for pricing: AI-powered pathology analysis products for translational research.
• PathAssist – Contact for pricing: AI-assisted pathology research tools, including dermatopathology applications.
• BioPharma services – Contact for pricing: Customized laboratory, translational research, and clinical development services.
• Real-world data products – Contact for pricing: Data and pathology insights for research and drug development.

Review

PathAI is a specialized solution for organizations that want to introduce artificial intelligence into digital pathology and tissue-image analysis. Its strongest advantage is the combination of digital slide management, AI-powered image analysis, and pathology expertise. Rather than offering only a single image-analysis algorithm, the company provides a broader ecosystem that includes AISight, specialized AI products, research datasets, and laboratory services.

AISight is particularly useful for pathology laboratories because it brings case management, image viewing, digital slide organization, and AI applications into one environment. Its compatibility with major scanner manufacturers and laboratory information systems is another advantage. The ability to work with third-party AI applications also gives laboratories more flexibility when selecting tools for different pathology specialties.

PathAI’s specialized algorithms provide additional value for biopharmaceutical research. Tools for biomarker quantification, tumor microenvironment analysis, and fibrosis assessment can help researchers produce more consistent measurements from tissue images. These capabilities are relevant to drug development, clinical trials, and precision medicine, where reproducible pathology measurements can contribute to the evaluation of treatment effects.

The company’s pathologist contributor network and large collection of annotated images are also important strengths. Expert annotations and carefully curated datasets support the development and evaluation of pathology AI models. Its collaborations with established healthcare and diagnostics organizations further demonstrate its relevance to professional laboratory and research environments.

However, PathAI is not designed for individual consumers or small teams looking for a simple, low-cost AI application. Its enterprise focus, specialized equipment requirements, and integration needs may make adoption more complicated. The company does not publish standard prices, so organizations must request commercial information and assess the total cost of implementation.

Another limitation is that different products have different intended uses and regulatory statuses. Research-use-only algorithms cannot automatically be treated as approved diagnostic tools. Laboratories must carefully evaluate product clearances, validation requirements, and regional regulations before using AI-generated results in clinical practice.

Overall, PathAI is a strong option for pathology laboratories, healthcare institutions, and biopharmaceutical organizations seeking advanced digital pathology and AI-based tissue analysis. Its integrated platform, specialized algorithms, and research services offer considerable value for professional applications. Its enterprise pricing, technical requirements, and product-specific regulatory limitations are important factors to consider before adoption.